Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1403 and mRNA-1405 Vaccines for Norovirus Acute Gastroenteritis in Healthy Adults
NCT05992935Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Aug 2023
- Primary completion
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of mRNA-1403, mRNA-1405 in Norovirus Acute Gastroenteritis, sponsored by Moderna Inc. Started Aug 2023; status: completed.
02
Drugs
mRNA-1403mRNA-1405
03
Conditions
Norovirus Acute Gastroenteritis
Beyond the preview
Go deeper on NCT05992935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05992935.